BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zakariassen HL, John LM, Lutz TA. Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. Basic Clin Pharmacol Toxicol 2020;127:163-77. [PMID: 32363722 DOI: 10.1111/bcpt.13427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022;7:298. [PMID: 36031641 DOI: 10.1038/s41392-022-01149-x] [Reference Citation Analysis]
2 Vagena E, Crneta J, Engström P, He L, Yulyaningsih E, Korpel NL, Cheang RT, Bachor TP, Huang A, Michel G, Attal K, Berrios DI, Valdearcos M, Koliwad SK, Olson DP, Yi CX, Xu AW. ASB4 modulates central melanocortinergic neurons and calcitonin signaling to control satiety and glucose homeostasis. Sci Signal 2022;15:eabj8204. [PMID: 35536884 DOI: 10.1126/scisignal.abj8204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Boyle CN, Zheng Y, Lutz TA. Mediators of Amylin Action in Metabolic Control. JCM 2022;11:2207. [DOI: 10.3390/jcm11082207] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cao J, Belousoff MJ, Liang YL, Johnson RM, Josephs TM, Fletcher MM, Christopoulos A, Hay DL, Danev R, Wootten D, Sexton PM. A structural basis for amylin receptor phenotype. Science 2022;375:eabm9609. [PMID: 35324283 DOI: 10.1126/science.abm9609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Lutz TA. Creating the amylin story. Appetite 2022. [DOI: 10.1016/j.appet.2022.105965] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-72. [PMID: 34798060 DOI: 10.1016/S0140-6736(21)01751-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee S. Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors. Biomolecules 2021;11:1364. [PMID: 34572577 DOI: 10.3390/biom11091364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Stein LM, McGrath LE, Lhamo R, Koch-Laskowski K, Fortin SM, Skarbaliene J, Baader-Pagler T, Just R, Hayes MR, Mietlicki-Baase EG. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats. Am J Physiol Regul Integr Comp Physiol 2021;321:R250-9. [PMID: 34259025 DOI: 10.1152/ajpregu.00337.2020] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Cabri W, Cantelmi P, Corbisiero D, Fantoni T, Ferrazzano L, Martelli G, Mattellone A, Tolomelli A. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Front Mol Biosci 2021;8:697586. [PMID: 34195230 DOI: 10.3389/fmolb.2021.697586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Fletcher MM, Keov P, Truong TT, Mennen G, Hick CA, Zhao P, Furness SG, Kruse T, Clausen TR, Wootten D, Sexton PM. AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther 2021;377:417-40. [DOI: 10.1124/jpet.121.000567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mathiesen DS, Lund A, Vilsbøll T, Knop FK, Bagger JI. Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Front Endocrinol (Lausanne) 2020;11:617400. [PMID: 33488526 DOI: 10.3389/fendo.2020.617400] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]